Similar items over time

Drug - Marplan (Isocarboxazid), Roche, circa 1965 Object Reg. No: SH 850264

Summary:
Marplan is the trade name for the drug isocarboxazid, one of the hydrazine class of antidepressants, manufactured by Roche, circa 1965. It was stocked in a psychiatric hospital pharmacy in Victoria, Australia. Isocarboxazid is a monoamine oxidase inhibitor (MAOI) and was prescribed for its antidepressant and anxiolytic properties. Due to its strength, significant side-effects and ability to react with some foods, Marplan was considered for patients for whom other antidepressant treatments had failed to have any effect, as a drug of last resort.
Description:
Drug Marplan (isocarboxazid) is in tablet-form contained in a small, flat, clear plastic box (sealed) inside which is blue and white cardboard packet, labelled MARPLAN. Originally held 200 but that has been crossed out and 100 substituted in handwriting.
Acquisition Information:
Donation from Office of Psychiatric Services
Discipline: History
Dimensions: 3.50 cm (Height), 1.00 cm (Width), 5.00 cm (Length)

More information

Tagged with: psychiatric hospitals, pharmaceuticals, hospitals, mental health, mental health institutions, psychiatric services, medicines, psychiatric institutions, medicinals drugs, drugs, making history - psych services
Themes this item is part of: Medicine in Society Collection, Psychiatric Services Collection, Public Life & Institutions Collection
Primary Classification: MEDICINE & HEALTH
Secondary Classification: Mental Health - Pharmacy
Tertiary Classification: pharmaceuticals
Inscriptions: Text: [200] Tablets/ 'MARPLAN'/ Trade Mark/ 100 (printed on front and back of packet)
Manufacturer: Roche, Australia, Circa 1965
Place Used: Victoria, Australia, Circa 1965
References: Martindale. The extra pharmacopoeia. London. Pharmaceutical Press. 1972.

Add your comment

  • Museum Victoria does not provide valuations, for more information please visit the valuation infosheet
  • Please note that Museum Victoria staff will not normally respond to comments posted on our website.
Yes No